Tumor-Infiltrating Lymphocytes in Wilms Tumor

Abstract

Purpose: T-lymphocytes-infiltrating tumors (TILs) are white blood cells (CD3+) found within the tumor and are thought to indicate a T-cell-mediated specific immune response. The purpose was to evaluate the presence and the subtypes of TILs in Wilms tumor (WT) specimens. Materials and Methods: A prospective study was conducted, and consecutive cases of WT registered and treated at our center were included in the study. The resected tumor was processed by taking multiple sections from the tumor and the peritumoral area. The sections were then processed for evaluating TILs and their subtypes (CD4 + and CD8+). TILs were assessed as a percentage of the total mononuclear cell infiltration in both these areas in all specimens. Results: Twenty-four consecutive specimens of WT were studied. The mean TILs (CD3+) counts was significantly higher (P = 0.001) in the peritumoral area (22.64 ± 1.42; range 20.2%–25%) as compared to the tumor (21.08 ± 2.42; range 14.6%–23.1%). The mean T-Helper (CD4+) counts was also significantly higher (P < 0.001) in the peritumoral area (13.04 ± 1.79; range 10.5%–16.5%) than in the tumor (7.30 ± 1.81; range 4.2%–10.1%). The mean cytolytic T-lymphocytes (CTLs-CD8+) counts in peritumoral area were 6.64 ± 1.09 (range 4.2%–9.2%), while in the tumor, it was 11.96 ± 3.09 (range 3.6%–16.4%). Two patients died on follow-up due to recurrence. These patients showed a markedly lower CD8+ cell count and higher CD4+/CD8+ ratio in the tumor. Conclusion: T-cells infiltration takes place in WT, and most of the patients demonstrate a higher concentration of CTL (CD8+) in the tumor as compared to the peritumoral area.

Keywords

Immunosurveillance - tumor-infiltrating lymphocytes - Wilms tumor

Publication History

Received: 12 May 2019

Accepted: 10 November 2019

Article published online:
23 May 2021

• References

• 1 Kreider JW, Bartlett GL, Butkiewicz BL. Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis. Cancer Metastasis Rev 1984; 3: 53-74
• 2 Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515: 577-81
• 3 Mao Y, Qu Q, Chen X, Huang O, Wu J, Shen K. The prognostic value of tumor-infiltrating lymphocytes in breast cancer: A systematic review and meta-analysis. PLoS One 2016; 11: e0152500
• 4 Yu X, Zhang Z, Wang Z, Wu P, Qiu F, Huang J. Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: A systematic review and meta-analysis. Clin Transl Oncol 2016; 18: 497-506
• 5 Li J, Wang J, Chen R, Bai Y, Lu X. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget 2017; 8: 15621-31
• 6 Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F. et al. Tumor infiltrating lymphocytes: An intriguing player in the survival of colorectal cancer patients. BMC Immunol 2010; 11: 19
• 7 Yao W, He JC, Yang Y, Wang JM, Qian YW, Yang T. et al. The prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: A systematic review and meta-analysis. Sci Rep 2017; 7: 7525
• 8 Liu H, Zhang T, Ye J, Li H, Huang J, Li X. et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother 2012; 61: 1849-56
• 9 Geng Y, Shao Y, He W, Hu W, Xu Y, Chen J. et al. Prognostic role of tumor-infiltrating lymphocytes in lung cancer: A meta-analysis. Cell Physiol Biochem 2015; 37: 1560-71
• 10 Baine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L. et al. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 2015; 6: 24990-5002
• 11 Lee N, Zakka LR, Mihm Jr. MC, Schatton T. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology 2016; 48: 177-87
• 12 Kim KJ, Lee KS, Cho HJ, Kim YH, Yang HK, Kim WH. et al. Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+cytotoxic T cells in microsatellite-unstable gastric cancers. Hum Pathol 2014; 45: 285-93
• 13 Mina M, Boldrini R, Citti A, Romania P, D’Alicandro V, De Ioris M. et al. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. Oncoimmunology 2015; 4: e1019981
• 14 Mochizuki K, Kawana S, Yamada S, Muramatsu M, Sano H, Kobayashi S. et al. Various checkpoint molecules, and tumor-infiltrating lymphocytes in common pediatric solid tumors: Possibilities for novel immunotherapy. Pediatr Hematol Oncol 2019; 36: 17-27
• 15 Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375-9
• 16 Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-48
• 17 Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L. et al. Immune-related strategies driving immunotherapy in breast cancer treatment: A real clinical opportunity. Expert Rev Anticancer Ther 2015; 15: 689-702
• 18 Vesely MD, Schreiber RD. Cancer immunoediting: Antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci 2013; 1284: 1-5
• 19 Qin A, Coffey DG, Warren EH, Ramnath N. Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. Cancer Med 2016; 5: 2567-78
• 20 Nagai K, Yamada A, Eguchi H, Kato H, Itoh K. HLA-A2402-restricted and tumor-specific cytotoxic T lymphocytes from tumor-infiltrating lymphocytes of a child with Wilms’ tumor. Pediatr Res 1997; 42: 122-7
• 21 Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F. et al. Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 18538-43